Ocugen

Ocugen

Yahoo Finance • yesterday

Ocugen to Participate in Upcoming August Investor Conferences

MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovat... Full story

Yahoo Finance • 19 days ago

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400 MALVERN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“... Full story

Yahoo Finance • last month

Ocugen to Participate in Upcoming July Industry Conferences

MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovat... Full story

Yahoo Finance • last month

Is Absci Corporation (ABSI) A Good Stock To Buy Now?

Is ABSI a good stock to buy? We came across a bullish thesis on Absci Corporation on TradersPro's Substack. In this article, we will summarize the bulls' thesis on ABSI. Absci Corporation's share was trading at $7.27 as of June 15th.Ocugen... Full story

Yahoo Finance • 2 months ago

Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now?

Is RAPP a good stock to buy? We came across a bullish thesis on Rapport Therapeutics, Inc. on TradersPro's Substack. In this article, we will summarize the bulls' thesis on RAPP. Rapport Therapeutics, Inc.'s share was trading at $38.26 as... Full story

Yahoo Finance • 2 months ago

Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy Now?

Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.'s share was trading at $... Full story

Yahoo Finance • 2 months ago

Russell 3000 Shuffle: Ocugen, Nektar slated to join among healthcare stocks; Nano-X to drop off

[Health Care sector, stock exchange monitor with index information.] Torsten Asmus The semi-annual rebalancing of U.S. equities is officially underway after FTSE Russell unveiled its preliminary list of shifts for the broad-market Russell... Full story

Yahoo Finance • 3 months ago

Biggest stock movers Tuesday: SHOP, INTC, DUOL, and more

[Business graph, chart green background.Copy space] design master Stock futures edged higher early Tuesday as investors tracked renewed Middle East tensions while eyeing key economic data later this week. Here are some of Tuesday's bigge... Full story

Yahoo Finance • 3 months ago

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and liv... Full story

Yahoo Finance • 4 months ago

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05)Potential 2X treatment benefit compared to 15% and 22% reductions reported for currently approve... Full story

Yahoo Finance • 4 months ago

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and... Full story

Yahoo Finance • 5 months ago

Midday Fly By: IEA to release 400M oil barrels, Oracle reports Q3 beat

The major averages were lower near noon, with the Dow dropping over 400 points as traders weigh shifting oil prices and a key inflation report. Markets are trading cautiously amid volatile energy prices and ongoing geopolitical tensions in... Full story

Yahoo Finance • 5 months ago

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * Ocugen (OCGN [https://seekingalpha.com/symbol/OCGN]) * Abercrombie & Fitch Co. (ANF [https://seekingalpha.com/symbol/ANF]) * XAI Octagon Floating Rate & Alternative Inc... Full story

Yahoo Finance • 5 months ago

Pre-Market Earnings Report for March 4, 2026 : DY, NXE, BBWI, ANF, WIX, EYE, EYPT, GENI, DAKT, STVN, OCGN, REAX

The following companies are expected to report earnings prior to market open on 03/04/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Dycom Industries, Inc. (DY)is reporting for the quarter ending Janua... Full story

Yahoo Finance • 5 months ago

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patientsTopline Phase 3 data expected in 1Q 20... Full story

Yahoo Finance • 6 months ago

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Ch... Full story

Yahoo Finance • 8 months ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

MALVERN, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, an... Full story

Yahoo Finance • 9 months ago

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA) provided acceptability of a single U.S.-b... Full story

Yahoo Finance • 10 months ago

Ocugen to Present at Industry and Investor Conferences in October 2025

MALVERN, Pa., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that executive leadership will present a... Full story

Yahoo Finance • 11 months ago

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25% of net salesOcugen to manufacture and supp... Full story